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1. Introduction 
Breast cancer is one the most important health concerns of the modern society (Ferlay et al., 
2007). Worldwide, it is estimated that over one million new cases of breast cancer are 
diagnosed every year, and more than 400 thousands will die from the breast cancer 
(Coughlin & Ekwueme, 2009) The life-time risk in women contracting breast cancers is 
estimated to be 1 in 8, which is the highest among all forms of cancers. (DevCan, 2004). 
Although the mortality rates from breast cancers have decreased in most developed 
countries because more frequent mammographic screening and extensive use of tamoxifen, 
it still remains the second highest in women (Clark, 2008). Breast cancer incidence rates were 
reported to have doubled or tripled in developing countries in the past 40 years (Anderson 
et al., 2008; Porter, 2008). The main options for breast cancer treatment include surgery, 
radiation therapy and chemotherapy (Mirshahidi & Abraham, 2004). Surgical procedures 
usually lead to significant morbidity such as lymph edema, muscle wasting, neuropathy and 
chronic pain (Paci et al., 1996). Radiation therapy is useful for cancer which is more localized, 
but it also carry a number of acute and chronic side- effects such as nausea, diarrhea, pain 
and fatigue (Ewesuedo & Ratain, 2003). Endocrine therapy may be used as a supplementary 
treatment. This method of therapy is applied to specific group of patients, e.g. women after 
menopause with hormone-responsive disease (Gradishar, 2005). In hormone-sensitive 
cancer patients receive chemotherapy with cytotoxic drugs. The cytotoxic drugs treat 
cancers by causing cell death or growth arrest. Effective cancer chemotherapy is able either 
to shrink a tumor or to help destroy cancer cells (Ewesuedo & Ratain, 2003). A number of 
obstacles such as drug toxicity, possible undesirable drug interactions and various forms of 
drug resistance have to be overcome to achieve effective chemotherapy (Cardosa et al., 2009). 
Drug resistance is a general problem in the chemotherapy of several cancers including 
breast cancers (Wong et al., 2006). Failures in treatment of cancers are common. 
Development of new drugs is also slow to progress. Among the reasons contributing to this 
are weak absorption, high rate of metabolism and elimination of drugs per oral 
administration resulting in less or variable concentrations in blood, poor drug solubility, 
unpredictable bioavailability of oral drugs due to food, and tissue toxicity (Sipos et al., 1997). 
Thus alternative methods of drug administration like appropriate drug carrier system is 
needed to overcome this problem. Depending on the route of administration, the size of 
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drug carriers may range from a few nanometers (colloidal carriers), to micrometers 
(microparticles) and to several millimeters (implants). Among these carriers, nanoparticles 
had shown great promise for parenteral application of chemotherapeutic drugs (Mehnert et 
al., 2001). Targeting of unhealthy tissues and organs of the body is one of the important 
challenges of the drug delivery systems. Nanoparticles seem to show promise as a drug 
targeting systems supplying drug to target tissues at the right time (Kayser et al., 2005). The 
main objective of new drug delivery systems is to improve the anti-tumor efficacy of drug 
and reduce their toxic effects on normal tissues. Nanoparticle is expected to be able to 
diminish toxicity of chemotherapy drug. Nanoparticles based on lipids that are solid at 
room temperature, namely solid lipid nanoparticle (SLN) using physiological well-tolerable 
lipids have potentially wide application (Siekmann & Westesen, 1992; Müller et al., 1995; 
Müller et al., 2000). The SLN is a drug delivery system that loads lipophilic or chemically 
unstable drugs (Fig. 1). Among the advantages of SLN are high potential for management of 
drug release and drug targeting, high stability for drug loading and high capacity for drug 
payload. This delivery system makes possible the encapsulation of lipophilic and 
hydrophilic drugs without the toxic effect of the carriers. This system also avoids the use  
 
Fig. 1. Electron microscopy picture of solid lipid nanoparticles made from Compritol® 
stabilized with poloxamer 188, diameter 400nm (Adapted from Müller and Mäder 2000) 
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organic solvents, and has potential for large scale production. However, several 
disadvantages are associated with SLNs to include particle growth, particle aggregation, 
unpredictable gelation tendency, polymorphic transitions, burst drug release and inherently 
low incorporation capacities due to the crystalline structure of the solid lipid (Mehnert & 
Mäder, 2001).  
The most common production technique of SLNs are high-pressure homogenization (HPH), 
high-shear homogenization combined with ultrasound, solvent emulsification/evaporation 
and microemulsion techniques. HPH is the predominant production method because it is 
easy to handle and scale-up. In this method, drug incorporation is achieved by dissolving or 
dispersing the drug in the melted lipid (He et al., 2007). The drug can be encapsulated in the 
matrix or attached to the particle surface. In spite of improved researches in production of 
high quality SLN, it is still not routinely used clinically.  
2. Tamoxifen-encapsulated solid lipid nanoparticles  
The chemical name of tamoxifen is trans-2-[4-(1,2-diphenyl-1-butenyl)phenoxyl] 
N,Ndimethylethylamine (Fig. 2). Tamoxifen, an antiestrogen molecule and strong 
hydrophobic drug (water solubility, 0.04 µg/mL at 37°C), is widely administered in breast 
cancer and high risk patients (McGregor & Jorda, 1998). Although tamoxifen was primarily 
used as a drug against hormone-dependent breast cancers (Wyld et al., 1998), it has also 
been used in the treatment of hormone-insensitive estrogen receptor-negative breast cancers 
(Jordan, 1994). Tamoxifen inhibits cell proliferation and induces apoptosis in breast cancer 
cells (MCF-7, MDA-MB231 and BT-20) (Mandlekar & Kong, 2001; Mandlekar et al., 2000). In 
spite of being high effective, tamoxifen has harmful dose-dependent long-term side-effects 
such as development of endometrial cancer (Brigger et al., 2001), hyperplasia, polyps, 
carcinoma, sarcoma (Peters-Engl et al., 1999; Cohen, 2004) vaginal hemorrhage, blazes and 
liquid retention in postmenopausal breast cancer patients (Mourits et al., 2001; Delima et al., 
2003). Formulations with the encapsulation of low-dose tamoxifen in colloidal delivery 
systems have been effective. Tamoxifen has been formulated in nanospheres such as poly-ε-
caprolactone  nanopart ic les  (Chawla  & Ami j i ,  2003)  and long c i rculat ing 
Poly(MePEGcyanoacrylate-co-hexadecylcyanoacrylate) nanoparticles in the form of free 
base (Brigger, et al., 2001). Tamoxifen, as a nonsteroidal antiestrogen drug was recently 
encapsulated in SLNs and was shown to be effective on induced mammary tumor gland in 
Sprague-Dawley rats (Abbasalipourkabir et al., 2010,1) in parenteral administration. The SLN  
 
Fig. 2. Chemical Structure of Tamoxifen (Adapted from Christov et al., 2007) 
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systems offer a sustained release of the drug in its intact form (Fontana et al., 2005 Using 
human breast cancer cell line, MCF7, some in vitro studies have shown that drug release 
from the tamoxifen-incorporated SLN has the same antitumoral activity as the free drug 
(Abbasalipourkabir et al., 2011). Therefore the tamoxifen-loaded SLN as a carrier system has 
excellent potential in prolonged drug release in breast cancer therapy (Fundaro et al., 2000).  
2.1 Preparation of tamoxifen-loaded SLN 
Drug‑loaded SLNs can be prepared using the high-pressure homogenization technique 
(Abbasalipourkabir et al., 2011). A mixture of Hydrogenated palm oil (Softisan 154 or 
S154) and Hydrogenated soybean lecithin (Lipoid S100-3, containing 90% 
phosphatidylcholine, including 12–16% palmitic acid, 83–88% stearic acid, oleic acid and 
isomers, and linoleic acid] at a ratio of 70:30 is grounded in a ceramic crucible. The 
mixture is heated to 65–70°C while being stirred with a PTFE-coated magnet until a clear-
yellowish lipid matrix (LM) solution is obtained. A solution containing 1 mL oleyl alcohol, 
0.005 g thimerosal, 4.75 g Sorbitol, and 89.25 mL bidistilled water (all w/w) at the same 
temperature is added to 5 g of LM. A pre-emulsion of SLN is obtained using the 
homogenizer (Ultra Turrax, Ika) at 13,000 rpm for 10 min and high-pressure homogenizer 
(EmulsiFlex-C50 CSA10, Avestin) at 1000 bar, 20 cycles, and 60 °C. The lipophilic drug 
tamoxifen (1 mg) is dissolved in oleyl alcohol and mixed with 5 mg of SLN pre‑emulsion 
using the Ultra Turrax homogenizer at 13,000 rpm for 10 min. This mixture is then 
incubated overnight at 50–60 °C, stirred periodically with a PTFE‑coated magnet at 500 
rpm, and finally will expose to air to solidify. 
2.2 In Vitro antitumoral activity of Tamoxifen-loaded solid lipid nanoparticle  
Cell death basically can occur in two ways. The first is through the necrosis pathway, where 
traumatic injuries cause cells damage in particular cell enlarges, bursts and liberate its 
intracellular components into the surrounding environment. The second pathway is 
programmed cell death or apoptosis, which is a molecular signaling cascade, inducing a 
disturbance in the organization and package of the cell causing death (Fadok, 1999; 
Messmer & Pfeilschifter, 2000). Other mode of cell death has also been suggested, for 
example mitotic cell death, which plays an important role in cell death caused by ionizing 
radiation (Steel, 2001). Breast cancer is the most common malignancy (18% of all 
malignancies) in women worldwide and its occurrence is slowly increasing (Salami & 
Karami-Tehrani, 2003). Like many cancers, breast cancer appears to be a result of high 
genetic damage that caused uncontrolled cellular proliferation and unusual apoptosis. These 
phenomena activate proto-oncogenes and inactivate tumor suppressor genes. These events 
can be activated by exposure of living cells to environmental, physical, chemical and/or 
biological carcinogens (Russo & Russo, 2002). The antiestrogen molecule, Tamoxifen (TAM) 
or trans-2-[4-(1,2-diphenyl-1-butenyl) phenoxyl]-N, N-dimethylethylamine, has been widely 
applied in treatment of breast cancer and high risk patients. Tamoxifen can reduce the 
occurrence of contralateral breast cancers by at least 40% (Fontana et al., 2005). Tamoxifen 
exhibits anti-estrogenic activity by binding to the intracellular estrogen receptor. The 
tamoxifen-estrogen receptor complex binds with DNA and can subsequent inhibit mRNA 
transcription and lead to cellular apoptosis (Chawla & Amiji, 2003). Recently 
nanoparticulate delivery systems in the form of nanospheres like poly- caprolactone 
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nanoparticles and long–circulating PEG-coated poly (MePEGcyanoacrylate-co-
hexadecylcyanoacrylate) nanoparticles in the form of free base have been used for tamoxifen 
encapsulation. The basis of this formulation is to obtain the necessary dose of drug at tumor 
location for a known period of time and reducing adverse effects on normal organs in the 
body (Chawla & Amiji, 2003). In recent years Delivering Tamoxifen within Solid Lipid 
Nanoparticles have been recommended. Animal models play an important role in cancer 
chemotherapy (Abbasalipourkabir et al., 2010,2). However, today there is increasing 
acceptation for in vitro tests as the method for determining cytotoxicity and viability of 
chemotherapeutic drugs. The reason for change lies partly in the limitations of animal 
models, to include financial considerations, time, and differences between animal and 
human metabolism. Finally, there is the moral pressure to reduce animal experimentation. 
In vitro tests are more likely to be reproducible. In general, the procedure involves the 
exposure of cells to a range of concentrations of the chemicals under test for a defined time 
and then to test for cell viability. Such tests are most easily performed in microtitre plates, 
which allow rapid quantitation of the results using a micrometer plate reader (Adams, 
1990). The responses of breast cancer cell lines are determined by cytotoxicity assay, cellular 
and nuclear morphology, apoptosis and cell cycle distribution. 
2.3 Cytotoxicity effect of TAM-loaded SLN on human breast cancer cells  
The TAM-loaded SLN has an equally efficient cytotoxic activity as free tamoxifen. Therefore 
TAM-loaded SLN preserves the antitumoral activity of the free drug. When TAM is 
incorporated into the SLN carrier system, its antitumoral activity is still maintained and 
formulating TAM by incorporating into SLN will potentially enhance the solubility of the 
drug through inclusion into the lipid phase and facilitating the entrapment of greater 
amounts of the drug in the SLN, suggesting that SLN is a good carrier for the drug (Fig. 3. & 
Fig. 4).  
 
Fig. 3. MCF-7 cells viability after 72 hours incubation with TAM and TAM-Loaded SLN 
formulation. The percentage of cell viability is expressed as a ratio of treated cells to the 
untreated control cells. Each point represents the mean ± standard deviation of 5 wells. 
(Adapted from Abbasalipourkabir, 2010). 
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Fig. 4. MDA-MB231 cells viability after 72 hours incubation with TAM and TAM-Loaded 
SLN formulation. The percentage of cell viability is expressed as a ratio of treated cells to the 
untreated control cells. Each point represents the mean ± standard deviation of 5 wells. 
(Adapted from Abbasalipourkabir, 2010). 
The IC50 of TAM and TAM-loaded SLN for MDA-MB231 cells (ER-negative or ER-
independent) is higher than for MCF-7 cells (ER-positive or ER-dependent), (Tables 1-2).  
 
Treatment 
 IC50 (µg/mL)  
24h 48h 72h 
TAM 13.45±0.46 13.00±0.98 12.50±0.91 
TAM-SLN 13.18a±0.66 12.50a±1.50 11.78b±0.18 
All value represent the means ± std. dev., (n=5) A,bmeans in each row with different superscripts are 
significantly different TAM = Tamoxifen; TAM-SLN = Tamoxifen-loaded solid lipid nanoparticle 
(Adapted from Abbasalipourkabir, 2010). 
Table 1. The IC50 of TAM and TAM-loaded SLN on MCF-7 cells after 24, 48 and 72h. 
 
Treatment 
 IC50 (µg/mL)  
24h 48h 72h 
TAM 17.21±1.44 16.87±1.97 15.97±0.86 
TAM-SLN 16.93±0.82 16.00±0.10 15.80±0.69 
All value represent the means ± std. dev., (n=5) TAM = Tamoxifen; TAM-SLN = Tamoxifen-loaded 
solid lipid nanoparticle (Adapted from Abbasalipourkabir, 2010). 
Table 2. The IC50 of TAM and TAM-loaded SLN on MDA-MB231 cells after 24, 48 and 72h. 
The mechanisms of ER-independent, TAM-induced apoptosis may be through the inhibition 
of protein kinase C. The IC50 value of tamoxifen for protein kinase C inhibition is 4 to 10 
times the concentration for ER inhibition in ER-positive cells. Therefore, the dose of 
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tamoxifen for treatment of patients with ER-positive breast cancer would have to be 
increased over the usual 20 mg per day used. High dose of tamoxifen might decrease the 
therapeutic index by increasing toxicity (Gelmann, 1996). It seems that improved 
cytotoxicity of incorporated drug is not dependent of the composition on the SLN. In fact it 
was reported that the IC50 value of drug-loaded SLN composed of different materials were 
lower than that of free drug solution (Yuan et al, 2008). There are at least two mechanisms 
that have been associated with the cytotoxicity of drug-loaded SLN. Using Doxorubicin 
(DOX)-loaded SLN, it was suggested that the first mechanism involves the release of DOX 
from DOX-SLN outside the cells, and the cytotoxicity of DOX is increased by the 
nanoparticles. The second mechanism suggested was, release of the drug inside the cell and 
thus produces greater cytotoxicity (Wong et al., 2006). 
2.4 Morphological changes of TAM-loaded SLN on human breast cancer cells 
Apoptotic cell death can be recognized under phase contrast and fluorescence inverted 
microscope after staining. This is the most practical method to identify cell morphological 
changes attributed to apoptotic cell death.  
2.4.1 Phase contrast microscopy 
TAM-loaded SLN treatments at concentrations equal to IC50, causes detachment of MCF-7 
and MDA-MB231 cells and loss of colony formation ability. These cells appear rounded-up 
and lose contact with neighboring cells (Fig. 5). The normal untreated MCF-7 and MDA-MB-
231 cells, however, appear healthy and exhibiting epithelial–like features and forming a 
monolayer on the surface of the culture flask. In the presence of TAM and TAM-loaded 
SLN, the viability of the both cells diminishes and the cancer cells loss their normal 
morphological characteristics, detaches, aggregates, and later develops apoptotic bodies. 
The detachment of cells in the presence of free TAM and TAM-loaded SLN suggests that 
tamoxifen is cytotoxic, even when incorporated in the SLN.  
  
Fig. 5. Phase contrast micrographs of MCF-7 cell (A) and MDA-MB231 cell (B) treated with 
TAM loaded SLN (12 µg/mL) (magnification x10). (Adapted from Abbasalipourkabir, 2010). 
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2.4.2 Nuclear morphology 
Cell death is either by physiological or pathological means. Physiological cell death is 
distinguished by apoptotic morphology, including chromatin condensation, membrane 
blebbing, internucleosomal degradation of DNA, and apoptotic body formation. 
Pathological cell death or necrosis is associated with cellular swelling and collapse, without 
severe damage to nuclei or breakdown of the DNA. In apoptosis, several cellular and 
molecular biological features, including cell shrinkage and DNA fragmentation are 
exhibited (Yu et al., 2010). To characterize the cell death, the nuclear morphology of dying 
cells can be examined under Hoechst dye 33258 staining. The Hoechst dye 33258 is a bis-
benzimide derivatives and a fluorescent DNA-binding agent. This dye is useful for cell cycle 
analysis because it can be used in low concentrations, and thus minimizing the problem of 
toxicity. According to Latt & Stetten, (1976) the Hoechst dye binds to AT-rich regions of the 
DNA and when excited with an ultraviolet light produces bright fluorescence at 465 nm. 
TAM-loaded SLN induce death of MCF-7 and MDA-MB231 cells by apoptosis. This is 
evident by the typical apoptotic changes showing clear condensation of cell nuclei, nuclear 
fragmentation and apoptotic bodies (Fig. 6). 
   
Fig. 6. Fluorescence microscopy of MCF-7 cells (A) and MDA-MB-231 cells (B) treated with 
TAM-loaded SLN. Cell shrinkage (thin arrow) and apoptotic cells (thick arrow) are evident 
(magnification x40). (Adapted from Abbasalipourkabir, 2010). 
Tamoxifen-loaded SLN like free TAM display antitumoral activity against human breast 
cancer cells. The biological availability of drug is not affected when incorporated into SLN. 
Therefore SLN could be applied as a drug delivery system for cancer treatments. In 
conclusion, the TAM-loaded SLN, because of its small size, could not be easily 
phagocytosed by macrophages and therefore the nanoparticles could be potentially used in 
long-term circulating carrier system for breast cancer therapy.  
3. Conclusion 
The main challenge in cancer chemotherapy is toxic side-effects induced by 
chemotherapeutic drugs. Single dose or short-time application (1-2 weeks) will probably 
causes serious health problems, but the use of biodegradable nano-sized particles for 
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long-term or life-time therapy may produce other serious side-effects. Increasing the 
encapsulation efficiency of poorly water-soluble molecules will lead to the development 
of improved SLN formulations. In the near future, it is expected more studies will focus 
on improving SLN and drug-loaded SLN formulations to increase the efficacy and reduce 
the side-effects of chemotherapeutic drugs for anticancer treatment. These studies should 
include preparation of formulations with different particle size and distributions, 
different matrix lipids and additional ingredients. Thus, if nanoparticulate drug delivery 
systems to be used effectively and routinely, the matter of toxicity of the components of 
nanoparticles must be addressed. Indeed, SLN requires further development before it can 
be used as a new drug delivery system for chemotherapy drugs in treatment of human 
cancers. 
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